Atezolizumab news

FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.

Phase Ib/II testing obrixtamig (DLL3/CD3 T‑cell engager) plus zoci (zocilurtatug pelitecan, DLL3 ADC) in ES‑SCLC and other NECs to assess safety, tolerability and early clinical activity

Phase Ib/II trial will test DLL3/CD3 T‑cell engager plus PD‑L1/VEGF‑A bispecific in extensive‑stage SCLC to boost durable antitumor immunity; dosing to start H2 2026

Tecentriq reduces death risk by 41% and recurrence by 36% in bladder cancer using ctDNA guidance, sparing low-risk patients from unnecessary treatment.

Roche presents over 30 abstracts on cancer treatments, including breast, lung, and bladder cancers, at ESMO 2025, showcasing significant advancements in progression-free and overall survival.